Emergent BioSolutions
Specialized products to healthcare providers and governments to address.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $250m | Post IPO Debt |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 15 % | (37 %) | (9 %) | (1 %) | (20 %) | 17 % | (31 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 29 % | (3 %) | (7 %) | 4 % | 18 % | 8 % | 10 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 13 % | (20 %) | (74 %) | (19 %) | 6 % | 7 % | (13 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 13 % | 17 % | 11 % | 7 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
At Emergent, we develop, manufacture, and deliver protections against public health threats. For more than two decades, we’ve been at work defending people from things we hope will never happen — so that we’re prepared, just in case they ever do.
Please note: It has come to our attention that there may be people posing as Emergent recruiters and hiring managers online, offering fraudulent opportunities to job seekers. Emergent will never ask for any financial commitment from a candidate as a pre-employment requirement. Learn more about recruitment fraud and how to protect yourself here: https://bit.ly/recruitment-fraud
Tech stack
Investments by Emergent BioSolutions
Edit
